Daunorubicin
Topoisomerase Inhibitor
DB00694
Approved Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
2
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Details
DrugBank ID
DB00694 ↗
Approval Date
2004-04-01
Molecular Weight
527.5199 g/mol
Drug Class
Topoisomerase Inhibitor
ATC Codes
L01DB02
Synonyms
(+)-Daunomycin, Acetyladriamycin, Daunomycin
PubChem
CID: 30323 ↗
ChEMBL
CHEMBL178 ↗
SMILES
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
ADMET Profile
Computing properties…